Self-Expanding TAVR: Conduction Abnormalities Jeffrey J. Popma, MD

Slides:



Advertisements
Similar presentations
Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Advertisements

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Conduction Disturbances after Percutaneous Aortic Valve Replacement Reducing Post-TAVR Conduction Disturbances UC a EE.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.
Percutaneous Aortic Valve Replacement without Predilatation for Symptomatic Severe Aortic Stenosis in High-Risk Patients Lev.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal Implantation Depth and Adherence to Guidelines.
1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
TAVR in Patients With Chronic Kidney Disease
VSD post TAVR: Mechanisms, Presentation and Management
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.
Jeffrey J. Popma, MD Director, Interventional Cardiology
CRT 2011 Washington DC, February 27th – March 1st
Extending the Boundaries of TAVR: Future Directions
A Review of Medtronic CoreValve TAVI Clinical Results:
Managing TAVI Rhythm Disturbances (New LBBB, Bradyarrhythmias, and Temporary and Permanent Pacemakers) Jeffrey J. Popma, MD Director, Interventional Cardiology.
TAVR Medtronic CoreValve® Subclavian Approach Clinical Data
TWELVE-LEAD INTERPRETATION
Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators
Are we ready to perform TAVI in Intermediate Risk Patients?
Ganesh Manoharan Consultant Cardiologist
Updates From NOTION: The First All-Comer TAVR Trial
TAVR-Endocarditis Tarek Chami, MD
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
Heart Valve Thrombosis & Neuro-Outcomes
MedStar Washington Hospital Center Cardiac Catheterization Conference
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
Predictors of Pacemaker Implantation With a Self-Expanding Repositionable Transcatheter Aortic Valve Ian T. Meredith AM, MBBS, PhD, FRACP FACC, FCSANZ,
Stroke After TAVR: Surgeon View
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
Giuseppe Tarantini MD, PhD
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
TAVI „Catch me if you can!“
The Impact of Live Case Transmission on Patient Outcomes during Transcatheter Aortic Valve Replacement: Results from the VERITAS Study Dr. Ron Waksman.
Early Feasibility Studies Investigator Perspective
Updates From SURTAVI in Intermediate Risk Patients
Lessons from complications: Balloon-Expandable Edwards SAPIEN and the Self-Expanding Medtronic CoreValve Sunday February 21, :10 – 4:20 pm, Diplomat.
Medtronic - Core Valve Eberhard Grube, MD, FACC, FSCAI
Department of Cardiology Bern University Hospital
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Progress with the Sadra Medical Lotus™ Valve System
Instituto de Ciencias del Corazón
Ganesh Manoharan Consultant Cardiologist
Κολπικη μαρμαρυγη σε ασθενεις με αποφρακτικη υπνικη απνοια
Timing of Intervention in Mitral Stenosis
Dynamic Mitral Valve Ring Annuloplasty: Micardia Concept
Balloon-Expandable Transcatheter Valve System : OUS Data
Kyle D Buchanan, MD MedStar Washington Hospital Center
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
The Guidelines Should Be Change!
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Volume 11, Issue 12, Pages (December 2014)
Volume 11, Issue 12, Pages (December 2014)
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
(A and B) Pressure tracings showing haemodynamic results pre-BAV (A) and post-BAV (B) procedure. (A and B) Pressure tracings showing haemodynamic results.
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Self-Expanding TAVR: Conduction Abnormalities Jeffrey J. Popma, MD Director, Interventional Cardiology Clinical Services Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical School Boston, MA

Conflict of Interest Statement Within the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) listed below. Physician Name Company/Relationship Jeffrey J. Popma, MD Research Grants: Cordis, Boston Scientific, Medtronic, Abbott-Guidant, eV3, LabCoat Medical Advisory Board: Cordis, Boston Scientific, Abbot Vascular Disclaimer: “Caution – Percutaneous Aortic Valves are investigational devices, limited by United States to Investigation use only.”

Managing Post TAVR Rhythm Disturbances Why Do They Occur? How Often Do Problems Develop? How Can we Predict Them? Who Should Receive PPMs?

The Triangle of Koch (Right Atrium) The atrioventricular node is contiguous to the membranous septum The origin of the LBBB and is found at the apex of the triangle of Koch Atrioventricular node Courtesy of Professor Damian Sanchez-Quintana

Conduction Abnormalities Piazza et al JACC CV Interv 2008;1;310-316

Permanent Pacemaker Need Khawaja Circulation. 2011;123:951-960

Managing Post TAVR Rhythm Disturbances Why Do They Occur? How Often Do Problems Develop? How Can we Predict Them? Who Should Receive PPMs? Left Bundle Branch Block AV Conduction Disturbances Complete Heart Block Permanent Pacemaker Use

CoreValve Implantation Case Day 1 post-procedure New onset LBBB Day 3 Post-procedure LBBB Serruys et al. Tips & Tricks to Avoid Failure (Informa Healthcare 2010)

New LBBB After CoreValve 30 day follow-up 65 46 38 39 40 % patients 30 Piazza N TVT2010 Seattle

EuroPCR: National Registries Outcomes Registry Pts Device Stroke PPM COR02-20061 72 Corevalve 7.1 25.4 Contemporary Registries Italian Registry2 772 CoreValve 1.7 18.5 Belgian Registry3 141 4 23.0 French Transfemoral4 66 3.6 26.9 UK CoreValve Registry5 417 NR 26.0 Total 1,396 Source Registry (Cohort 1) 6 463 Edwards 4.0 8 Appropriate PPM may be < 20% EuroPCR2010: 1 Gerckens et al; 2Petronio et al; 3 Bosmans et al; 4 Eltchaninoff et al; 5 Ludman et al; 6 Thomas et al

Other Contemporary Series Italian Registry: New PPM in 17.4% at 30 Days Tamburino Circulation. 2011;123:299-308 Hospital Universitario N=181 EuroPCR 2011 P=0.007 34.5 Hazard Ratio P Value Depth of Implant 1.15 0.001 RBBB 3.08 0.007 Standard 59 14 STD Accutrak

Managing Post TAVR Rhythm Disturbances Why Do They Occur? How Often Do Problems Develop? How Can we Predict Them? Who Should Receive PPMs?

Permanent Pacemaker Need 270 patients from 10 clinical center in UK 8% of patients with prior PPM LBBB 13% at baseline  61% after procedure 33.3% new permanent pacemaker requirement Baseline conduction abnormalities - Baseline RBBB  65.2% PPM - Base LBBB  43.75% PPM - Normal QRS complex  27.6% PPM Median time to PPM implant, 4 days Multivariable predictors: AV block, balloon predilation, use of 29 mm valve, IV septum diameter, prolonged QRS Khawaja Circulation. 2011;123:951-960

Predictors of Permanent Pacemaker Placement Jilaihawi et al. Am Heart J 2009 LBBB +left axis deviation Thickness of non-coronary leaflet Septal wall thickness Bleiziffer et al. JACC Interv 2010 Intra-operative AV block Borderline small annulus size Baan et al. Am Heart J 2010 Small LVOT Left axis deviation Mitral annular calcification Latsios et al. CCI 2010 Aortic valve calcification (MSCT) Female gender Left ventricular dysfunction

Conduction Abnormalities After CoreValve Depth of Implantation Relates to PPM Requirements Piazza JACC Interventions 2008; 1: 310

Predictors of New LBBB and PPM Pulmonary hypertension Septal wall thickness Right bundle branch block Depth of implant from non-coronary leaflet Depth of implant from left coronary leaflet Multivariable Analysis Piazza et al. EuroIntervention 2010 (in press)

What Are We Doing to Reduce This? Sizing of pre-dilation balloon based on minimal diameter of the CTA to lessen trauma to membranous septum Shorter pre-dilatation balloon length Rapid ventricular pacing CoreValve sizing based on CTA annular diameter Accutrek deployment system High implantation deph (< 6 mm) Follow ACC/AHA for PPM Judicious use EPS to determine HV intervals

Managing Post TAVR Rhythm Disturbances Why Do They Occur? How Often Do Problems Develop? How Can we Predict Them? Who Should Receive PPMs?

Managing Post TAVR Rhythm Disturbances

HV Interval and Complete Heart Block Three major prospective studies have shown prolonged HV intervals (> 70ms) predict patients at higher risk of AV block. Even in highest risk patients (HV > 80msec and symptomatic) rate of CHB approaches 6%/yr -- > low PPV Patients with HV interval great than 100msec (rare) are at extreme high risk by all accounts.

Baseline Chronic Fascicular Block Epstein et al JACC Vol. 51, No. 21, 2008; e1–62

Baseline Chronic Fascicular Block Epstein et al JACC Vol. 51, No. 21, 2008; e1–62

Atrial Fibrillation Post TAVR 138 patients without prior atrial fibrillation New onset atrial fibrillation in 31.9% with 72 hours Predictive factors of AF were left atrial size (odds ratio [OR]: 1.21 for each increase in 1 mm/m2) and transapical approach (OR: 4.08, 95% CI: 1.35 to 12.31, p = 0.019). Cumulative stroke and stroke/systemic embolism rates at FU in the NOAF group were 13.6% and 15.9% in the NOAF group vs. 3.2% in the no-NOAF group (p = 0.039, adjusted p = 0.037 for stroke; p = 0.020, adjusted p = 0.023 for stroke/systemic embolism). Amat-Santo J Am Coll Cardiol 2012;59:178–88

Preventative Measurement: PPM Pre-procedural PPM when indicated Undersized, shorter BAV balloon ? Avoid oversizing device High (< 6 mm implantation) Temporary pacemaker x 48 hours AHA/ACC Indications for PPM EP study may assist